Full results and data from this multiple ascending dose Phase 1 study of NKTR-181 have been accepted for presentation at the 2012 American Academy of Pain Medicine's 28th Annual Meeting to be held February 23 – 26, 2012."These exciting clinical results underscore our enthusiasm for advancing NKTR-181 into Phase 2 development in chronic pain patients," said Robert Medve, MD, Chief Medical Officer at Nektar Therapeutics. "As a new mu-opioid analgesic molecule that does not rely on a formulation approach, NKTR-181 has the potential to transform the treatment of chronic pain by providing effective pain relief with less CNS-related side effects than traditional opioid therapies. Our clinical results to-date suggest that NKTR-181 exhibits a continuous analgesic effect over a 12-hour period, with a slower rate of entry into the CNS, which could greatly reduce its potential dangerous CNS-related side effects and the euphoria that leads to abuse of traditional opioids. We look forward to initiating our Phase 2 clinical study of NKTR-181 in mid-2012."
Nektar Announces Positive Clinical Data From Second Phase 1 Clinical Study Of NKTR-181, A Novel Opioid Analgesic Molecule To Treat Chronic Pain
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.